No efficacy or safety data were disclosed. EvolveImmune has dosed the first subject in EIU-104101 (NCT07217171), a first-in-human Phase 1 study of EVOLVE104, a trispecific T cell engager that binds CD3 and CD2 on T cells and targets ULBP2/5/6 on tumor cells. The dose-escalation/expansion trial will enroll up to 160 subjects with locally advanced or metastatic urothelial carcinoma and a range of squamous cell carcinomas, assessing safety, pharmacokinetics, and preliminary antitumor activity.
The core move is straightforward: the company’s EVOLVE platform is now in the clinic with what it positions as the first ULBP2/5/6-directed T cell engager and a built-in costimulatory mechanism via CD2. The design follows a familiar basket strategy, starting with Phase 1a dose escalation to establish a recommended Phase 2 dose, followed by Phase 1b expansion cohorts across urothelial and squamous histologies of the lung, esophagus, skin, tongue, and anogenital region. Target selection reflects a stress ligand family reportedly enriched across epithelial cancers, creating a potential path to pan-squamous application if expression and accessibility are adequate in human tumors.
Strategically, this is an attempt to differentiate in a crowded engager field by tackling the two hard problems in solid tumors: insufficient activation and an immunosuppressive microenvironment. Integrating CD2 costimulation into a CD3 engager is a deliberate pivot away from CD28- or 4-1BB-based co-stimulation strategies that have drawn both enthusiasm and safety scrutiny, and it allows the company to steer clear of over-contested antigens like Trop-2 or CLDN18.2. The multi-histology footprint is a signal-finding bet and a hedge: it broadens the chance of early activity while preserving optionality to narrow into the most responsive indications in Phase 1b and beyond.
For sites and CROs, this is a high-touch solid-tumor engager program with the usual operational demands: step-up dosing logic, intensive early-cycle monitoring, and well-drilled pathways for cytokine release syndrome and neurotoxicity management. The planned 160-subject size points to a multi-center footprint across academic and large community sites. If enrollment is not gated by a ULBP2/5/6 assay, screening may be faster but the signal risk is higher due to expression heterogeneity; if biomarker confirmation is used, expect added logistics for central testing and potential re-biopsy in squamous cancers where archival tissue is often inadequate. Vendors supporting cytokine panels, T-cell activation biomarkers, and centralized RECIST reads will be critical, and DSMB cadence will matter given the first-in-class format.
Regulatory attention will center on exposure–response, immunogenicity, and evidence that integrated costimulation does not elevate high-grade CRS/ICANS beyond manageability. Trispecific engineering raises CMC complexity—stability, aggregation, and manufacturability will need early, transparent de-risking to keep escalation on schedule. Clinically, the bar in post–PD-1 urothelial and head and neck settings has been reshaped by ADCs; any signal will be weighed against toxicity, ease of administration, and potential combination value. A credible biomarker plan for ULBP2/5/6 expression and pharmacodynamic readouts will be important to support indication prioritization and regulatory dialogue.
Near-term, watch for initial dose-escalation safety contours: incidence and grade of CRS, feasibility of outpatient management after initial cycles, and whether step-up dosing achieves target exposure without premed-heavy regimens. Early hints of activity in bladder and head and neck could drive expansion cohort selection and combination testing with anti–PD-1 agents. Clarity on whether expression-based enrichment is required in Phase 1b will signal how the company intends to balance operational speed against proof-of-biology. A mid-2026 safety update is a reasonable expectation; any manufacturing or site-activation delays would be an early red flag for scalability of the trispecific format.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
